The Binaytara Foundation has proudly announced the 2023 Binaytara Career Advancement Awards recipients. The recipients of the 2023 awards attended…
By: BTF Staff October 28, 2023 – Known for its unwavering commitment to improving access to cancer care in…
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), significantly improves overall survival (OS) in renal cell…
By: Dr. Anam Kamal Ascension Providence Hospital; Michigan The standard of care for such patients is platinum-based doublet chemotherapy. In…
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On October 27, the U.S. Food and Drug Administration approved toripalimab-tpzi (Loqtorzi) in combination…
By: Dr. Kanak Parmar On October 24, 2023 the U.S. Food and Drug Administration approved ivosidenib for adult patients with…
By Dr. Kanak Parmer Texas Tech University Health Sciences Center On October 16,2023 the U.S. Food and Drug Administration…
By Dr. Lei DengAssistant Professor/Medical OncologistThoracic, Head & Neck Medical OncologyUniversity of Washington/Fred Hutchinson Cancer Centerhttps://youtu.be/QVW-vify1x8Transcript:Dr. Deng: "Hi everyone! Welcome…
MARIPOSA-2: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal…
By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in…